Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 4/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775030 | 0.91 | HTR6 (0.34) | HTR6HSD11B1PGRALDH1A1MAPK1 | |
| SCHEMBL5779413 | 0.89 | BRD4 (0.34) | HTR6HSD11B1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5776176 | 0.88 | DDB1 (0.36) | HSD11B1PGRALDH1A1 | |
| SCHEMBL5777951 | 0.88 | HTR6 (0.38) | HTR6PGR | |
| SCHEMBL5777138 | 0.88 | HSD11B1 (0.39) | HTR6HSD11B1ALDH1A1LMNAMAPT | |
| SCHEMBL5777170 | 0.87 | CHRNA1 (0.36) | HSD11B1 | |
| SCHEMBL5775724 | 0.86 | GAA (0.41) | HTR6ALDH1A1MAPT | |
| SCHEMBL5775190 | 0.86 | GSK3B (0.35) | HSD11B1PGR | |
| SCHEMBL5775758 | 0.83 | HSD11B1 (0.38) | HSD11B1PGR | |
| SCHEMBL5775027 | 0.81 | ALDH1A1 (0.34) | HSD11B1PGRALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406888-B1 | SUBSTITUTED Y-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2006-05-24 | — | — | EP | claimed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | claimed |
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406888-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004483-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| EP-1406888-B1 | SUBSTITUTED Y-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2006-05-24 | — | — | EP | disclosed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | disclosed |
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406888-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004483-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRIN1, GRIN3A, GRIK5 | HTR6 1156/4885ITGAL 1939/4885BACE1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.